Physician profile
Michael Edward Nash
NPI 1770587271
$3,602.06
in general payments reported to CMS, 2019-2025
35 companies · $25.02 in 2025
The $25.02 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,005 · 2020: $422 · 2021: $13.03 · 2023: $115 · 2024: $22.00 · 2025: $25.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $140 · Education: $22.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $140.05 |
| Education | $22.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $381.45 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $344.06 | 2019-2020 | |
| Genentech USA, INC. | $339.52 | 2019-2020 | |
| Pfizer INC. | $257.89 | 2019-2020 | |
| Astellas Pharma US INC | $252.94 | 2019-2025 | Vyloy |
| Incyte Corporation | $179.57 | 2019 | |
| Novartis Pharmaceuticals Corporation | $171.53 | 2019-2020 | |
| Amgen INC. | $126.96 | 2019 | |
| Exelixis INC. | $125.82 | 2019 | |
| Sobi, INC | $115.03 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.36 | 2019-2020 | |
| Eli Lilly and Company | $108.10 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $96.16 | 2019 | |
| Tesaro, INC. | $94.49 | 2019 | |
| Lilly USA, LLC | $89.91 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $75.73 | 2019 | |
| Janssen Biotech, INC. | $71.20 | 2019 | |
| Rigel Pharmaceuticals, INC. | $71.08 | 2019 | |
| Dova Pharmaceuticals | $67.38 | 2019-2020 | |
| Seagen INC. | $60.16 | 2019-2020 | |
| Verastem, INC. | $57.37 | 2019 | |
| Genzyme Corporation | $54.62 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $46.46 | 2019 | |
| Puma Biotechnology, INC. | $43.52 | 2019 | |
| Daiichi Sankyo INC. | $39.62 | 2019-2020 | |
| Taiho Oncology, INC. | $36.98 | 2019-2020 | |
| Eisai INC. | $35.07 | 2019 | |
| Gilead Sciences, INC. | $30.45 | 2019 | |
| Abbvie INC. | $24.26 | 2019 | |
| Janssen Pharmaceuticals, INC | $22.00 | 2024 | Rybrevant |
| Ipsen Biopharmaceuticals, INC | $18.31 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.12 | 2020 | |
| Alexion Pharmaceuticals, INC. | $13.96 | 2019 | |
| Pharmacosmos Therapeutics INC. | $13.03 | 2021 | |
| Foundation Medicine, INC. | $11.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Nash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.